Using	O
a	O
graphical	O
risk	O
tool	O
to	O
examine	O
willingness	B:C0243095
to	I:C0243095
take	I:C0243095
migraine	O
prophylactic	O
medications	O

Using	O
a	O
graphical	O
risk	O
tool	O
to	O
examine	O
willingness	O
to	I:C0243095
take	I:C0243095
migraine	B:C0149931
prophylactic	O
medications	O

Using	O
a	O
graphical	O
risk	O
tool	O
to	O
examine	O
willingness	O
to	I:C0243095
take	I:C0243095
migraine	O
prophylactic	B:C0199176
medications	O

Using	O
a	O
graphical	O
risk	O
tool	O
to	O
examine	O
willingness	O
to	I:C0243095
take	I:C0243095
migraine	O
prophylactic	O
medications	B:C0013227

Many	O
migraine	B:C0149931
sufferers	O
use	O
daily	O
prophylactic	O
therapy	I:C0199176
to	O
reduce	O
the	O
frequency	O
of	O
their	O
headache	O
attacks	O
.	O

Many	O
migraine	O
sufferers	O
use	O
daily	O
prophylactic	B:C0199176
therapy	I:C0199176
to	O
reduce	O
the	O
frequency	O
of	O
their	O
headache	O
attacks	O
.	O

Many	O
migraine	O
sufferers	O
use	O
daily	O
prophylactic	O
therapy	I:C0199176
to	O
reduce	O
the	O
frequency	O
of	O
their	O
headache	B:C0018681
attacks	O
.	O

The	O
Food	B:C0041714
and	I:C0041714
Drug	I:C0041714
Administration	I:C0041714
has	O
approved	O
several	O
different	O
medications	O
for	O
migraine	O
prophylaxis	O
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	O
perceive	O
these	O
treatments	O
to	O
provide	O
clinically	O
significant	O
benefits	O
given	O
their	O
side	O
effect	I:C0879626
profiles	O
.	O

The	O
Food	O
and	I:C0041714
Drug	I:C0041714
Administration	I:C0041714
has	O
approved	O
several	O
different	O
medications	B:C0013227
for	O
migraine	O
prophylaxis	O
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	O
perceive	O
these	O
treatments	O
to	O
provide	O
clinically	O
significant	O
benefits	O
given	O
their	O
side	O
effect	I:C0879626
profiles	O
.	O

The	O
Food	O
and	I:C0041714
Drug	I:C0041714
Administration	I:C0041714
has	O
approved	O
several	O
different	O
medications	O
for	O
migraine	B:C0149931
prophylaxis	O
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	O
perceive	O
these	O
treatments	O
to	O
provide	O
clinically	O
significant	O
benefits	O
given	O
their	O
side	O
effect	I:C0879626
profiles	O
.	O

The	O
Food	O
and	I:C0041714
Drug	I:C0041714
Administration	I:C0041714
has	O
approved	O
several	O
different	O
medications	O
for	O
migraine	O
prophylaxis	B:C0199176
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	O
perceive	O
these	O
treatments	O
to	O
provide	O
clinically	O
significant	O
benefits	O
given	O
their	O
side	O
effect	I:C0879626
profiles	O
.	O

The	O
Food	O
and	I:C0041714
Drug	I:C0041714
Administration	I:C0041714
has	O
approved	O
several	O
different	O
medications	O
for	O
migraine	O
prophylaxis	O
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	O
perceive	O
these	O
treatments	B:C0087111
to	O
provide	O
clinically	O
significant	O
benefits	O
given	O
their	O
side	O
effect	I:C0879626
profiles	O
.	O

The	O
Food	O
and	I:C0041714
Drug	I:C0041714
Administration	I:C0041714
has	O
approved	O
several	O
different	O
medications	O
for	O
migraine	O
prophylaxis	O
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	O
perceive	O
these	O
treatments	O
to	O
provide	O
clinically	O
significant	O
benefits	O
given	O
their	O
side	B:C0879626
effect	I:C0879626
profiles	O
.	O

The	O
Food	O
and	I:C0041714
Drug	I:C0041714
Administration	I:C0041714
has	O
approved	O
several	O
different	O
medications	O
for	O
migraine	O
prophylaxis	O
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	O
perceive	O
these	O
treatments	O
to	O
provide	O
clinically	O
significant	O
benefits	O
given	O
their	O
side	O
effect	I:C0879626
profiles	B:C1979963
.	O

Three	O
hundred	O
headache	B:C0018681
sufferers	O
were	O
recruited	O
from	O
the	O
community	O
and	O
local	O
headache	O
clinics	O
using	O
print	O
and	O
television	O
advertising	O
.	O

Three	O
hundred	O
headache	O
sufferers	O
were	O
recruited	O
from	O
the	O
community	O
and	O
local	B:C0205276
headache	O
clinics	O
using	O
print	O
and	O
television	O
advertising	O
.	O

Three	O
hundred	O
headache	O
sufferers	O
were	O
recruited	O
from	O
the	O
community	O
and	O
local	O
headache	B:C0018681
clinics	O
using	O
print	O
and	O
television	O
advertising	O
.	O

Three	O
hundred	O
headache	O
sufferers	O
were	O
recruited	O
from	O
the	O
community	O
and	O
local	O
headache	O
clinics	B:C0442592
using	O
print	O
and	O
television	O
advertising	O
.	O

Participants	B:C0679646
reported	O
experiencing	O
problematic	O
headache	O
attacks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
frequency	O
of	O
7.0	O
(	O
4	O
-	O
13	O
)	O
headache	O
days	O
per	O
month	O
.	O

Participants	O
reported	O
experiencing	O
problematic	O
headache	B:C0018681
attacks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
frequency	O
of	O
7.0	O
(	O
4	O
-	O
13	O
)	O
headache	O
days	O
per	O
month	O
.	O

Participants	O
reported	O
experiencing	O
problematic	O
headache	O
attacks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
frequency	O
of	O
7.0	O
(	O
4	O
-	O
13	O
)	O
headache	B:C0018681
days	O
per	O
month	O
.	O

These	O
sufferers	O
participated	O
in	O
a	O
cross-sectional	B:C0010362
,	I:C0010362
single	I:C0010362
-	I:C0010362
site	I:C0010362
,	I:C0010362
study	I:C0010362
that	O
used	O
a	O
specially	O
designed	O
computer	O
assessment	O
task	O
.	O

Participants	B:C0679646
were	O
instructed	O
on	O
the	O
probability	O
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	O
effects	I:C0879626
for	O
several	O
blinded	O
medication	O
profiles	O
:	O
divalproex	O
sodium	I:C0886883
,	O
venlafaxine	O
,	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	O
.	O

Participants	O
were	O
instructed	O
on	O
the	O
probability	O
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	B:C0879626
effects	I:C0879626
for	O
several	O
blinded	O
medication	O
profiles	O
:	O
divalproex	O
sodium	I:C0886883
,	O
venlafaxine	O
,	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	O
.	O

Participants	O
were	O
instructed	O
on	O
the	O
probability	O
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	O
effects	I:C0879626
for	O
several	O
blinded	B:C0150108
medication	O
profiles	O
:	O
divalproex	O
sodium	I:C0886883
,	O
venlafaxine	O
,	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	O
.	O

Participants	O
were	O
instructed	O
on	O
the	O
probability	O
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	O
effects	I:C0879626
for	O
several	O
blinded	O
medication	B:C0013227
profiles	O
:	O
divalproex	O
sodium	I:C0886883
,	O
venlafaxine	O
,	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	O
.	O

Participants	O
were	O
instructed	O
on	O
the	O
probability	O
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	O
effects	I:C0879626
for	O
several	O
blinded	O
medication	O
profiles	B:C1979963
:	O
divalproex	O
sodium	I:C0886883
,	O
venlafaxine	O
,	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	O
.	O

Participants	O
were	O
instructed	O
on	O
the	O
probability	O
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	O
effects	I:C0879626
for	O
several	O
blinded	O
medication	O
profiles	O
:	O
divalproex	B:C0886883
sodium	I:C0886883
,	O
venlafaxine	O
,	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	O
.	O

Participants	O
were	O
instructed	O
on	O
the	O
probability	O
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	O
effects	I:C0879626
for	O
several	O
blinded	O
medication	O
profiles	O
:	O
divalproex	O
sodium	I:C0886883
,	O
venlafaxine	B:C0078569
,	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	O
.	O

Participants	O
were	O
instructed	O
on	O
the	O
probability	O
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	O
effects	I:C0879626
for	O
several	O
blinded	O
medication	O
profiles	O
:	O
divalproex	O
sodium	I:C0886883
,	O
venlafaxine	O
,	O
gabapentin	B:C0060926
,	O
propranolol	O
,	O
and	O
topiramate	O
.	O

Participants	O
were	O
instructed	O
on	O
the	O
probability	O
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	O
effects	I:C0879626
for	O
several	O
blinded	O
medication	O
profiles	O
:	O
divalproex	O
sodium	I:C0886883
,	O
venlafaxine	O
,	O
gabapentin	O
,	O
propranolol	B:C0033497
,	O
and	O
topiramate	O
.	O

Participants	O
were	O
instructed	O
on	O
the	O
probability	O
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	O
effects	I:C0879626
for	O
several	O
blinded	O
medication	O
profiles	O
:	O
divalproex	O
sodium	I:C0886883
,	O
venlafaxine	O
,	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	B:C0076829
.	O

After	O
learning	O
the	O
likelihood	O
of	O
experiencing	O
side	B:C0879626
effect	I:C0879626
profiles	O
of	O
each	O
medication	O
,	O
participants	O
were	O
asked	O
whether	O
they	O
would	O
be	O
willing	O
to	I:C0243095
take	I:C0243095
the	O
medication	O
for	O
a	O
given	O
headache	O
reduction	O
level	O
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days	O
per	O
month	O
.	O

After	O
learning	O
the	O
likelihood	O
of	O
experiencing	O
side	O
effect	I:C0879626
profiles	B:C1979963
of	O
each	O
medication	O
,	O
participants	O
were	O
asked	O
whether	O
they	O
would	O
be	O
willing	O
to	I:C0243095
take	I:C0243095
the	O
medication	O
for	O
a	O
given	O
headache	O
reduction	O
level	O
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days	O
per	O
month	O
.	O

After	O
learning	O
the	O
likelihood	O
of	O
experiencing	O
side	O
effect	I:C0879626
profiles	O
of	O
each	O
medication	B:C0013227
,	O
participants	O
were	O
asked	O
whether	O
they	O
would	O
be	O
willing	O
to	I:C0243095
take	I:C0243095
the	O
medication	O
for	O
a	O
given	O
headache	O
reduction	O
level	O
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days	O
per	O
month	O
.	O

After	O
learning	O
the	O
likelihood	O
of	O
experiencing	O
side	O
effect	I:C0879626
profiles	O
of	O
each	O
medication	O
,	O
participants	B:C0679646
were	O
asked	O
whether	O
they	O
would	O
be	O
willing	O
to	I:C0243095
take	I:C0243095
the	O
medication	O
for	O
a	O
given	O
headache	O
reduction	O
level	O
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days	O
per	O
month	O
.	O

After	O
learning	O
the	O
likelihood	O
of	O
experiencing	O
side	O
effect	I:C0879626
profiles	O
of	O
each	O
medication	O
,	O
participants	O
were	O
asked	O
whether	O
they	O
would	O
be	O
willing	B:C0243095
to	I:C0243095
take	I:C0243095
the	O
medication	O
for	O
a	O
given	O
headache	O
reduction	O
level	O
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days	O
per	O
month	O
.	O

After	O
learning	O
the	O
likelihood	O
of	O
experiencing	O
side	O
effect	I:C0879626
profiles	O
of	O
each	O
medication	O
,	O
participants	O
were	O
asked	O
whether	O
they	O
would	O
be	O
willing	O
to	I:C0243095
take	I:C0243095
the	O
medication	B:C0013227
for	O
a	O
given	O
headache	O
reduction	O
level	O
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days	O
per	O
month	O
.	O

After	O
learning	O
the	O
likelihood	O
of	O
experiencing	O
side	O
effect	I:C0879626
profiles	O
of	O
each	O
medication	O
,	O
participants	O
were	O
asked	O
whether	O
they	O
would	O
be	O
willing	O
to	I:C0243095
take	I:C0243095
the	O
medication	O
for	O
a	O
given	O
headache	B:C0018681
reduction	O
level	O
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days	O
per	O
month	O
.	O

The	O
side	B:C0879626
effect	I:C0879626
profile	O
for	O
divalproex	O
sodium	I:C0886883
was	O
associated	O
with	O
the	O
smallest	O
willingness	I:C0243095
to	I:C0243095
take	I:C0243095
,	O
with	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	O
perceived	O
to	O
be	O
much	O
more	O
agreeable	O
.	O

The	O
side	O
effect	I:C0879626
profile	B:C1979963
for	O
divalproex	O
sodium	I:C0886883
was	O
associated	O
with	O
the	O
smallest	O
willingness	I:C0243095
to	I:C0243095
take	I:C0243095
,	O
with	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	O
perceived	O
to	O
be	O
much	O
more	O
agreeable	O
.	O

The	O
side	O
effect	I:C0879626
profile	O
for	O
divalproex	B:C0886883
sodium	I:C0886883
was	O
associated	O
with	O
the	O
smallest	O
willingness	I:C0243095
to	I:C0243095
take	I:C0243095
,	O
with	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	O
perceived	O
to	O
be	O
much	O
more	O
agreeable	O
.	O

The	O
side	O
effect	I:C0879626
profile	O
for	O
divalproex	O
sodium	I:C0886883
was	O
associated	O
with	O
the	O
smallest	B:C0243095
willingness	I:C0243095
to	I:C0243095
take	I:C0243095
,	O
with	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	O
perceived	O
to	O
be	O
much	O
more	O
agreeable	O
.	O

The	O
side	O
effect	I:C0879626
profile	O
for	O
divalproex	O
sodium	I:C0886883
was	O
associated	O
with	O
the	O
smallest	O
willingness	I:C0243095
to	I:C0243095
take	I:C0243095
,	O
with	O
gabapentin	B:C0060926
,	O
propranolol	O
,	O
and	O
topiramate	O
perceived	O
to	O
be	O
much	O
more	O
agreeable	O
.	O

The	O
side	O
effect	I:C0879626
profile	O
for	O
divalproex	O
sodium	I:C0886883
was	O
associated	O
with	O
the	O
smallest	O
willingness	I:C0243095
to	I:C0243095
take	I:C0243095
,	O
with	O
gabapentin	O
,	O
propranolol	B:C0033497
,	O
and	O
topiramate	O
perceived	O
to	O
be	O
much	O
more	O
agreeable	O
.	O

The	O
side	O
effect	I:C0879626
profile	O
for	O
divalproex	O
sodium	I:C0886883
was	O
associated	O
with	O
the	O
smallest	O
willingness	I:C0243095
to	I:C0243095
take	I:C0243095
,	O
with	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	B:C0076829
perceived	O
to	O
be	O
much	O
more	O
agreeable	O
.	O

However	O
,	O
<	O
60	O
%	O
of	O
participants	B:C0679646
reported	O
willingness	O
to	I:C0243095
take	I:C0243095
any	O
of	O
these	O
medications	O
even	O
if	O
they	O
provided	O
a	O
50	O
%	O
reduction	O
in	O
headache	O
frequency	O
.	O

However	O
,	O
<	O
60	O
%	O
of	O
participants	O
reported	O
willingness	B:C0243095
to	I:C0243095
take	I:C0243095
any	O
of	O
these	O
medications	O
even	O
if	O
they	O
provided	O
a	O
50	O
%	O
reduction	O
in	O
headache	O
frequency	O
.	O

However	O
,	O
<	O
60	O
%	O
of	O
participants	O
reported	O
willingness	O
to	I:C0243095
take	I:C0243095
any	O
of	O
these	O
medications	B:C0013227
even	O
if	O
they	O
provided	O
a	O
50	O
%	O
reduction	O
in	O
headache	O
frequency	O
.	O

However	O
,	O
<	O
60	O
%	O
of	O
participants	O
reported	O
willingness	O
to	I:C0243095
take	I:C0243095
any	O
of	O
these	O
medications	O
even	O
if	O
they	O
provided	O
a	O
50	O
%	O
reduction	O
in	O
headache	B:C0018681
frequency	O
.	O

Several	O
general	O
predictors	O
of	O
willingness	B:C0243095
to	I:C0243095
take	I:C0243095
were	O
observed	O
including	O
high	O
headache	O
-	O
related	O
disability	O
,	O
depressive	O
symptoms	I:C0086132
,	O
and	O
pain	O
medication	I:C0002771
concerns	O
including	O
fear	O
of	O
tolerance	O
.	O

Several	O
general	O
predictors	O
of	O
willingness	O
to	I:C0243095
take	I:C0243095
were	O
observed	O
including	O
high	O
headache	B:C0018681
-	O
related	O
disability	O
,	O
depressive	O
symptoms	I:C0086132
,	O
and	O
pain	O
medication	I:C0002771
concerns	O
including	O
fear	O
of	O
tolerance	O
.	O

Several	O
general	O
predictors	O
of	O
willingness	O
to	I:C0243095
take	I:C0243095
were	O
observed	O
including	O
high	O
headache	O
-	O
related	O
disability	B:C0231170
,	O
depressive	O
symptoms	I:C0086132
,	O
and	O
pain	O
medication	I:C0002771
concerns	O
including	O
fear	O
of	O
tolerance	O
.	O

Several	O
general	O
predictors	O
of	O
willingness	O
to	I:C0243095
take	I:C0243095
were	O
observed	O
including	O
high	O
headache	O
-	O
related	O
disability	O
,	O
depressive	B:C0086132
symptoms	I:C0086132
,	O
and	O
pain	O
medication	I:C0002771
concerns	O
including	O
fear	O
of	O
tolerance	O
.	O

Several	O
general	O
predictors	O
of	O
willingness	O
to	I:C0243095
take	I:C0243095
were	O
observed	O
including	O
high	O
headache	O
-	O
related	O
disability	O
,	O
depressive	O
symptoms	I:C0086132
,	O
and	O
pain	B:C0002771
medication	I:C0002771
concerns	O
including	O
fear	O
of	O
tolerance	O
.	O

Several	O
general	O
predictors	O
of	O
willingness	O
to	I:C0243095
take	I:C0243095
were	O
observed	O
including	O
high	O
headache	O
-	O
related	O
disability	O
,	O
depressive	O
symptoms	I:C0086132
,	O
and	O
pain	O
medication	I:C0002771
concerns	O
including	O
fear	B:C0015726
of	O
tolerance	O
.	O

Several	O
general	O
predictors	O
of	O
willingness	O
to	I:C0243095
take	I:C0243095
were	O
observed	O
including	O
high	O
headache	O
-	O
related	O
disability	O
,	O
depressive	O
symptoms	I:C0086132
,	O
and	O
pain	O
medication	I:C0002771
concerns	O
including	O
fear	O
of	O
tolerance	B:C0220929
.	O

These	O
findings	B:C0243095
suggest	O
that	O
if	O
properly	O
informed	O
of	O
the	O
side	O
effect	I:C0879626
profiles	O
of	O
these	O
medications	O
,	O
many	O
patients	O
might	O
opt	O
for	O
other	O
treatments	O
.	O

These	O
findings	O
suggest	O
that	O
if	O
properly	O
informed	O
of	O
the	O
side	B:C0879626
effect	I:C0879626
profiles	O
of	O
these	O
medications	O
,	O
many	O
patients	O
might	O
opt	O
for	O
other	O
treatments	O
.	O

These	O
findings	O
suggest	O
that	O
if	O
properly	O
informed	O
of	O
the	O
side	O
effect	I:C0879626
profiles	B:C1979963
of	O
these	O
medications	O
,	O
many	O
patients	O
might	O
opt	O
for	O
other	O
treatments	O
.	O

These	O
findings	O
suggest	O
that	O
if	O
properly	O
informed	O
of	O
the	O
side	O
effect	I:C0879626
profiles	O
of	O
these	O
medications	B:C0013227
,	O
many	O
patients	O
might	O
opt	O
for	O
other	O
treatments	O
.	O

These	O
findings	O
suggest	O
that	O
if	O
properly	O
informed	O
of	O
the	O
side	O
effect	I:C0879626
profiles	O
of	O
these	O
medications	O
,	O
many	O
patients	O
might	O
opt	O
for	O
other	O
treatments	B:C0087111
.	O

